One-page summary of programs, stack, and status.
Damaged myocardium does not reliably regenerate. Virelion works on biological and computational approaches to restore function after injury.
Gene therapy VB-101 candidate identification.
Scaffold & biomaterials VB-204 graft concepts.
Protein & drug discovery target prioritization (major focus).
Computational platform VB-310 / HeartTwin + open stack.
Open-source measurement (OptiCell, ElectroTrace, MyoTrace), safety (CardioScore, Biosafety), and HeartTwin orchestration with CardiSim and evaluation tools. 20+ public repositories under Virelion-Biotech.
Research-stage. No clinical trials. First architecture release: DOI 10.5281/zenodo.22680867.
Syed Umer Hannan, Founder · virelion85@gmail.com
github.com/Virelion-Biotech · virelionbiotech.netlify.app
Print this page or save as PDF from the browser for a one-page summary.
